AARP Vermont recently released findings from an April 2025 survey conducted by ANR Market Research of Burlington adults aged 45 and older. The results reveal a community deeply committed to staying put—81% want to remain in Burlington as they age—yet face mounting challenges that could push them out. High property taxes, rising utility bills, aging housing stock, and limited mobility options are making it harder for residents to maintain their independence and stay in the neighborhoods they call home.
A new AARP survey, released in conjunction with Social Security’s 90th anniversary, confirms that Americans highly value Social Security, and even more so than five years ago. The vast majority of Americans – 95% of Republicans, 98% of Democrats, and 93% of Independents – consider Social Security vital to the financial security of all Americans, and 67% believe it is even more important for retirees than it was five years ago.
Would you like to see a park located near the new Transit Center in Montpelier that provides connectivity to the bike path and access to the river? If so, please join VT River Conservancy (VRC) & AARP VT on Tuesday, December 4th to hear about the Confluence River Park in the heart of downtown Montpelier. This park will be located on the One Taylor Street parcel, at the confluence of the North Branch and main stems of the Winooski River. VRC has contracted with an engineering and design firm to create a Conceptual Design for the park. Come hear about the process and timeline, offer input to make this park age-friendly by sharing your priorities for a Confluence River Park. What would you like to see at a Montpelier riverside park? How would you use it? We want to hear from you!
AARP Vermont is presenting its most prestigious award for community service to Linda Bowden, a lead volunteer for livable communities and an advisory council member.
Retail prices for many of the most commonly-used brand name drugs by older adults rocketed upward by an average of 8.4 percent in 2017, outstripping the general inflation rate of 2.1 percent. The annual average cost of therapy for just one brand name drug increased to almost $6,800 in 2017.